Children with achondroplasia who took a class of injected peptide drugs grew about 1.36 centimeters more per year than children who did not, a little over half an inch of extra height annually. What the drugs did not do was change the body proportions that define the condition.
That is the headline from a meta-analysis published June 16 ↗ in the Journal of the Endocrine Society, the first to pool the trial evidence for C-type natriuretic peptide analogs, the drug class built to treat achondroplasia at its root.
What the drugs are for
Achondroplasia is the most common form of short-limbed dwarfism, and almost all of it traces to a single overactive gene. A mutation leaves the FGFR3 receptor stuck partly on, and an always-on FGFR3 puts a brake on the growth plates where children's long bones lengthen. The bones stop early and stay short.
C-type natriuretic peptide, or CNP, is the body's natural counter-signal to that brake. The two drugs in the analysis are engineered versions of it. Vosoritide, sold by BioMarin as Voxzogo and given as a daily injection, and navepegritide, a longer-acting version from Ascendis Pharma, both push back on the FGFR3 signal to let the growth plates keep working.
What the pooled trials showed
The authors, led by groups in Bangladesh, Birmingham, and Manchester, screened the literature and found 11 studies covering 542 children. Four of them were randomized controlled trials with a low risk of bias, totaling 326 children, and those four carried the main analysis.
On growth, the result held up. Annualized growth velocity, the speed a child gains height in a year, rose by 1.36 centimeters per year (95 percent confidence interval 1.05 to 1.68), a range that stays comfortably above zero. Standing height rose by 1.24 centimeters (0.47 to 2.01), and a height score that compares each child against typical growth charts improved by 0.28 points (0.20 to 0.37). Small numbers, but real and repeatable across the trials.
Then the part the growth figures do not capture. The ratio between the upper and lower halves of the body, the measurement that captures achondroplasia's disproportion, did not move (mean difference -0.02, confidence interval -0.04 to 0.01). The drugs made children taller. They did not make them proportionally taller in the way that drives the disability and the medical complications, at least not over the trial windows studied.
The safety picture
On safety, the analysis was reassuring on the things that count most. Overall and serious adverse event rates were no higher than placebo. The excess risk was concentrated at the needle. Injection site reactions were about 1.65 times as common, hives roughly four times as common (relative risk 4.04), and local swelling about 3.6 times as common. For a drug injected into children for years, the tolerability of the injection itself is not a footnote.
Why it matters
The growth-velocity gain is the number that wins approvals, and it is solid. The unchanged proportion ratio is the more honest measure of how far these drugs are from a cure. Achondroplasia's hardest problems, spinal stenosis, breathing trouble in infancy, the mechanics of disproportionate limbs, are tied to shape, not just height. A drug that adds half an inch a year and leaves the proportions where they were is a meaningful gain for some families and a smaller one than the height figures alone suggest. The meta-analysis is useful precisely because it puts both numbers on the same page.